Evidence mapPaperPMID 35670824Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2022

Network pharmacology approach and molecular docking to explore the potential mechanism of Wu-Wei-Wen-Tong Chubi capsules in rheumatoid arthritis.

Xiaoya Cui, Jian Liu, Lili Zhang, Xiaoli Wang, Xiaochuang Liu, Hui Jiang

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Xiaoya CuiClinical Research Experiment Center, The First Affiliated Hospital of Anhui University of Chinese Medicine, No. 117, Meishan Road, Shushan District, Hefei, 230031, Anhui, China.
Jian LiuClinical Research Experiment Center, The First Affiliated Hospital of Anhui University of Chinese Medicine, No. 117, Meishan Road, Shushan District, Hefei, 230031, Anhui, China.
Lili ZhangClinical Research Experiment Center, The First Affiliated Hospital of Anhui University of Chinese Medicine, No. 117, Meishan Road, Shushan District, Hefei, 230031, Anhui, China.
Xiaoli WangCollege of Pharmacy, Anhui University of Chinese Medicine, Hefei, Anhui, People's Republic of China.
Xiaochuang LiuClinical Research Experiment Center, The First Affiliated Hospital of Anhui University of Chinese Medicine, No. 117, Meishan Road, Shushan District, Hefei, 230031, Anhui, China.
Hui JiangClinical Research Experiment Center, The First Affiliated Hospital of Anhui University of Chinese Medicine, No. 117, Meishan Road, Shushan District, Hefei, 230031, Anhui, China. jianghui@ahtcm.edu.cn.
Anhui University of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Network pharmacology, a holistic approach based on the theory of biological network technology, integrates information from biological systems, drugs, and diseases. Here, this theory was used to predict the targets of Wu-Wei-Wen-Tong Chubi capsule (WWWT) to explore the mechanism in the treatment of rheumatoid arthritis (RA). The ingredients of each herbal medicine in WWWT were collected from the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP), and the active ingredients were screened through bioavailability (OB) ≥30% and drug-likeness (DL) ≥ 0.18. SwissTargetPrection and TCMSP were utilized to calculate and predict the targets of active ingredients. RA-related targets were obtained by searching the Genecards and OMIM databases. The common targets of RA and WWWT were used for gene ontology (GO), KEGG pathway enrichment, protein-protein interaction (PPI) analysis, and molecular docking. And then, four key genes were screened for subsequent verification experiments. In total, 90 active compounds and 330 potential targets of WWWT, 1310 targets of RA, and 135 intersection targets were found. Additionally, GO and pathway analysis identified 4610 significant GO terms and 147 significant KEGG pathways. Based on the PPI network, 11 key genes including IL-6, MMP-9, and TNF-α were screened out for molecular docking. Molecular docking showed that these key genes have good binding activities to active compounds of WWWT such as oroxylin a, kaempferol, and luteolin. Simultaneously, Western blot experimental validation demonstrated that the protein expressions of IL-6, MMP-9, TNF-α, and VEGFA significantly decreased after WWWT treatment. The mechanism of WWWT in treating RA involves multiple active compounds acting on multiple targets, and multiple pathways, which provides an important reference for further elucidation the mechanism and clinical applications of WWWT in the treatment of RA.

Indexed as

Arthritis, RheumatoidDrugs, Chinese HerbalCapsulesHumansInterleukin-6Matrix Metalloproteinase 9Molecular Docking SimulationNetwork PharmacologyTumor Necrosis Factor-alphaCapsulesDrugs, Chinese HerbalInterleukin-6Matrix Metalloproteinase 9Tumor Necrosis Factor-alphamolecular dockingnetwork pharmacologyrheumatoid arthritisWu-Wei-Wen-Tong Chubi capsule

Identifiers

PMID35670824
OpenAlexW4281875245

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.